Data gathered: May 4
AI Stock Analysis - CERo Therapeutics (CERO)
Analysis generated November 20, 2024. Powered by Chat GPT.
CERo Therapeutics is a pioneering company in the field of biotechnology, specializing in the development of novel therapies aimed at treating chronic and acute medical conditions. The company employs cutting-edge research methodologies and advanced technologies to innovate and improve therapeutic options. Despite its promising fundamentals, the stock price and market performance of CERo Therapeutics have experienced significant volatility, drawing both investor attention and scrutiny.
Stock Alerts - CERo Therapeutics (CERO)
 |
CERo Therapeutics | April 30 Price is down by -7.2% in the last 24h. |
|
CERo Therapeutics | April 25 Price is down by -14.4% in the last 24h. |
|
CERo Therapeutics | April 24 Price is up by 15.3% in the last 24h. |
|
CERo Therapeutics | April 23 Price is up by 11.3% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for CERo Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 95 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 67 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,366 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 16 | Sign up | Sign up | Sign up |
About CERo Therapeutics
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
| Price | $0.85 |
| Target Price | Sign up |
| Volume | 316,310 |
| Market Cap | $4.8M |
| Year Range | $0.59 - $28.53 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaApril 30 - GlobeNewswire |
|
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual MeetingApril 25 - GlobeNewswire |
|
 |
CERo Therapeutics (NASDAQ:CERO) Raised to Strong-Buy at D Boral CapitalApril 24 - ETF Daily News |
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaApril 24 - GlobeNewswire |
|
 |
CERo Therapeutics (NASDAQ:CERO) Coverage Initiated at D. Boral CapitalApril 23 - ETF Daily News |
CERo Therapeutics, Inc. Announces Up to $8 Million Series D FinancingApril 22 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 2.6M | -2.6M | -4.2M | -4.4M | -0.085 |
| Q2 '24 | 450,000 | 2.4M | -2M | -2.4M | -2.1M | -0.151 |
| Q1 '24 | 71,000 | 2.8M | -2.7M | -1.7M | -2M | -0.156 |
| Q4 '23 | 8.8M | 1.7M | 7M | -280,000 | -370,000 | -0.045 |
| Q3 '23 | 0 | 430,000 | -430,000 | -1.3M | -430,000 | -0.053 |
Insider Transactions View All
| YK Bioventures Opportunities Fund I, L.P. filed to sell 13,005,169 shares at $0.1. December 13 '24 |
| YK Bioventures Opportunities Fund I, L.P. filed to sell 16,004,077 shares at $0.1. December 13 '24 |
| YK Bioventures Opportunities Fund I, L.P. filed to sell 17,618,618 shares at $0.1. December 13 '24 |
| YK Bioventures Opportunities Fund I, L.P. filed to sell 18,962,419 shares at $0.1. December 10 '24 |
| YK Bioventures Opportunities Fund I, L.P. filed to sell 20,533,366 shares at $0.1. December 10 '24 |
Similar companies
Read more about CERo Therapeutics (CERO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, news mentions, customer reviews & linkedin employees.
What is the Market Cap of CERo Therapeutics?
The Market Cap of CERo Therapeutics is $4.8M.
What is the current stock price of CERo Therapeutics?
Currently, the price of one share of CERo Therapeutics stock is $0.85.
How can I analyze the CERO stock price chart for investment decisions?
The CERO stock price chart above provides a comprehensive visual representation of CERo Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling CERo Therapeutics shares. Our platform offers an up-to-date CERO stock price chart, along with technical data analysis and alternative data insights.
Does CERO offer dividends to its shareholders?
As of our latest update, CERo Therapeutics (CERO) does not offer dividends to its shareholders. Investors interested in CERo Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of CERo Therapeutics?
Some of the similar stocks of CERo Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.